why do pbms have different rules for glp-1 coverage Payers should lean on as they weigh GLP-1s GLP-1 Management Brief | Rightway

Data from a total of 7,215 study participants were used

Cardiovascular outcome trials (CVOTs) have consistently validated the safety of GLP-1RAs in individuals with type 2 diabetes, with several studies also demonstrating their potential to reduce stroke risk [37]

However, its essential to work with a healthcare provider to ensure that the combination of medications is safe and effective for you

Tirzepatide (Mounjaro/Zepbound) follows a similar principle

Several factors contribute to the pricing of these medications, including: Manufacturing costs Market demand Insurance coverage Regulatory influences Understanding these elements can help demystify the costs involved